Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Danirixin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 known ✓ | P25025 | 20/20 | 1.00 |
| ▸ | CX3CR1 | P49238 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Danirixin SCHEMBL29815122 | 1.00 | CXCR2 (1.00) | CXCR2CX3CR1 | |
| Danirixin SCHEMBL9959547 | 1.00 | CXCR2 (1.00) | CXCR2CX3CR1 | |
| Danirixin SCHEMBL12662221 | 1.00 | CXCR2 (1.00) | CXCR2CX3CR1 | |
| Danirixin SCHEMBL1199232 | 1.00 | CXCR2 (1.00) | CXCR2CX3CR1 | |
| Danirixin SCHEMBL29537761 | 1.00 | CXCR2 (1.00) | CXCR2CX3CR1 | |
| SCHEMBL1197995 | 0.94 | CXCR2 (1.00) | CXCR2CX3CR1 | |
| SCHEMBL12843897 | 0.94 | CXCR2 (1.00) | CXCR2CX3CR1 | |
| SCHEMBL1198597 | 0.91 | CXCR2 (1.00) | CXCR2CX3CR1 | |
| SCHEMBL12662220 | 0.91 | CXCR2 (1.00) | CXCR2CX3CR1 | |
| SCHEMBL1199231 | 0.91 | CXCR2 (1.00) | CXCR2CX3CR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 436 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026099526-A1 | COMBINATION OF INHIBITORS OF IL-1BETA, CCR5 OR CXCR2 CYTOKINE RECEPTORS FOR USE IN THE TREATMENT OF METASTASIS | FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA (ES) | 2026-05-15 | — | — | WO | claimed |
| US-20250376522-A1 | Targeting Cells with a Combination of CXCR2 Inhibition and CD47 Blockade | UNIV LELAND STANFORD JUNIOR (US) | 2025-12-11 | — | — | US | claimed |
| US-20250295611-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | TESSELLATE THERAPEUTICS INC (US) | 2025-09-25 | — | — | US | claimed |
| WO-2025151629-A2 | METHODS AND COMPOSITIONS FOR TREATING DISEASES ASSOCIATED WITH INFLAMMATION, PAIN AND/OR LESIONS | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2025-07-17 | — | — | WO | claimed |
| WO-2025097146-A1 | METHODS FOR CHARACTERIZING AND TREATING MULTIPLE MYELOMA | ROSWELL PARK CANCER INSTITUTE CORPORATION (US) | 2025-05-08 | — | — | WO | claimed |
| US-20250017878-A1 | USE OF NADOLOL TO TREAT CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY BLOCKAGE OF THE ARRESTIN-2 PATHWAY | CHRONIC AIRWAY THERAPEUTICS LTD (AU) | 2025-01-16 | — | — | US | claimed |
| WO-2024189434-A1 | USE OF NADOLOL TO TREAT PULMONARY SYMPTOMS ASSOCIATED WITH INFECTIONS WITH SARS-CoV-2 | CHRONIC AIRWAY THERAPEUTICS LIMITED (AU) | 2024-09-19 | — | — | WO | claimed |
| EP-4378957-A2 | COMBINATION THERAPIES COMPRISING ANTIBODY MOLECULES TO PD-1 | Novartis AG (CH) | 2024-06-05 | — | — | EP | claimed |
| US-20240148765-A1 | COMPOSITIONS AND METHODS FOR TREATING AND/OR PREVENTING THERAPY-RELATED CARDIOMYOPATHY ASSOCIATED WITH NEUTROPHIL INFILTRATION | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2024-05-09 | — | — | US | claimed |
| US-20240148745-A1 | COMPOUNDS FOR USE IN PROGRESSIVE MULTIPLE SCLEROSIS | FONDAZIONE CENTRO SAN RAFFAELE (IT) | 2024-05-09 | — | — | US | claimed |
| US-20160264525-A1 | HYDROBROMIDE SALT OFN-(4-CHLORO-2-HYDROXY-3-((3S)-3-PIPERIDINYLSULFONYL)PHENYL-N'-(3-FLUORO-2-METHYLPHENYL)UREA | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2016-09-15 | — | — | US | claimed |
| WO-2015071235-A1 | HYDROBROMIDE SALT OFN-(4-CHLORO-2-HYDROXY-3-((3S)-3-PIPERIDINYLSULFONYL)PHENYL-N'-(3-FLUORO-2-METHYLPHENYL)UREA | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2015-05-21 | — | — | WO | claimed |
| EP-2009992-B1 | IL-8 RECEPTOR ANTAGONISTS | GLAXOSMITHKLINE LLC (US) | 2012-06-27 | — | — | EP | claimed |
| US-20110105563-A1 | IL-8 RECEPTOR ANTAGONISTS | BUSCH-PETERSEN JAKOB | 2011-05-05 | — | — | US | claimed |
| US-20110059937-A1 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION | 2011-03-10 | — | — | US | claimed |
| US-7893089-B2 | IL-8 receptor antagonists | GlaxoSmithKline, LLC (US) | 2011-02-22 | — | — | US | claimed |
| US-20090093451-A1 | IL-8 Receptor Antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 2009-04-09 | — | — | US | claimed |
| EP-2009992-A2 | IL-8 RECEPTOR ANTAGONISTS | SmithKline Beecham Corporation (US) | 2009-01-07 | — | — | EP | claimed |
| WO-2007124424-A2 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-11-01 | — | — | WO | claimed |
| US-20070249672-A1 | IL-8 Receptor Antagonists | GLAXOSMITHKLINE LLC | 2007-10-25 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105563-A1 | IL-8 RECEPTOR ANTAGONISTS | CXCL8, CCR8, IL1RN | CXCR2 12/4885CX3CR1 33/4885 |
| US-20250017878-A1 | USE OF NADOLOL TO TREAT CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY BLOCKAGE OF THE ARRESTIN-2 PATHWAY | ARRB1, ADRB2, ADRB1 | CXCR2 146/4885CX3CR1 225/4885 |
| US-20070249672-A1 | IL-8 Receptor Antagonists | CXCL8, CCR8, IL1RN | CXCR2 12/4885CX3CR1 33/4885 |
| US-20110059937-A1 | IL-8 RECEPTOR ANTAGONISTS | CXCL8, CCR8, IL1RN | CXCR2 12/4885CX3CR1 33/4885 |
| US-20250295611-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | HTR2A, HTR5A, HTR6 | CXCR2 1756/4885CX3CR1 1040/4885 |
| US-20160264525-A1 | HYDROBROMIDE SALT OFN-(4-CHLORO-2-HYDROXY-3-((3S)-3-PIPERIDINYLSULFONYL)PHENYL-N'-(3-FLUORO-2-METHYLPHENYL)UREA | PNN, POLN, NCL | CXCR2 4160/4885CX3CR1 4758/4885 |
| US-20090093451-A1 | IL-8 Receptor Antagonists | CXCL8, CCR8, IL1RN | CXCR2 12/4885CX3CR1 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.